Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03067324
Other study ID # 38RC14.041
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 11, 2017
Est. completion date July 1, 2021

Study information

Verified date October 2020
Source University Hospital, Grenoble
Contact Sandrine LABLANCHE, MD, PhD
Phone +33 4 76 63 54 26
Email SLablanche@chu-grenoble.fr
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Islet quality control after pancreatic islets isolation process is insufficient. The Islet Chip study proposes to develop a bio-sensor that will allow a multi-parametric analysis of islet graft based on measurement of islet membrane electric potential.


Description:

Islet quality control after pancreatic islets isolation process is insufficient. The Islet Chip study proposes to develop a bio-sensor that will allow a multi-parametric analysis of islet graft based on measurement of islet membrane electric potential. The project aims to : - develop the bio-sensor necessary to measure islet membrane electric potential - develop interface between bio-sensor and user - correlate analysis data collected by bio-sensor with metabolic results of islet graft


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date July 1, 2021
Est. primary completion date December 31, 2020
Accepts healthy volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Patients enrolled in STABILOT Pancreatic Islet cell graft protocol and willing to participate to ISLET CHIP Exclusion Criteria: - Patients not enrolled in STABILOT Pancreatic Islet cell graft or patients that signed the form expressing their refuse to participate to ISLET CHIP.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
France Besançon University Hospital Besancon
France Clermont Ferrand University hospital Clermont-Ferrand
France Grenoble University Hospital Grenoble
France Lyon University Hospital Lyon
France Montpellier University Hospital Montpellier
France Nancy University hospital Nancy
France University hospital of Strasbourg Strasbourg
Switzerland Geneva University Hospital Geneva

Sponsors (2)

Lead Sponsor Collaborator
University Hospital, Grenoble University Hospital, Bordeaux

Countries where clinical trial is conducted

France,  Switzerland, 

References & Publications (6)

Gruessner RW, Gruessner AC. The current state of pancreas transplantation. Nat Rev Endocrinol. 2013 Sep;9(9):555-62. doi: 10.1038/nrendo.2013.138. Epub 2013 Jul 30. Review. — View Citation

Kusnik-Joinville O, Weill A, Salanave B, Ricordeau P, Allemand H. Prevalence and treatment of diabetes in France: trends between 2000 and 2005. Diabetes Metab. 2008 Jun;34(3):266-72. doi: 10.1016/j.diabet.2008.01.005. Epub 2008 Jun 3. — View Citation

Lablanche S, Borot S, Wojtusciszyn A, Bayle F, Tétaz R, Badet L, Thivolet C, Morelon E, Frimat L, Penfornis A, Kessler L, Brault C, Colin C, Tauveron I, Bosco D, Berney T, Benhamou PY; GRAGIL Network. Five-Year Metabolic, Functional, and Safety Results of Patients With Type 1 Diabetes Transplanted With Allogenic Islets Within the Swiss-French GRAGIL Network. Diabetes Care. 2015 Sep;38(9):1714-22. doi: 10.2337/dc15-0094. Epub 2015 Jun 11. — View Citation

Lebreton F, Pirog A, Belouah I, Bosco D, Berney T, Meda P, Bornat Y, Catargi B, Renaud S, Raoux M, Lang J. Slow potentials encode intercellular coupling and insulin demand in pancreatic beta cells. Diabetologia. 2015 Jun;58(6):1291-9. doi: 10.1007/s00125-015-3558-z. Epub 2015 Mar 19. — View Citation

Renaud S, Catargi B, Lang J. Biosensors in diabetes : how to get the most out of evolution and transpose it into a signal. IEEE Pulse. 2014 May-Jun;5(3):30-4. doi: 10.1109/MPUL.2014.2309577. Review. — View Citation

Ricordi C, Lacy PE, Finke EH, Olack BJ, Scharp DW. Automated method for isolation of human pancreatic islets. Diabetes. 1988 Apr;37(4):413-20. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Beta-score Beta-score in continuous variable, using the last Beta-score known before the second islet graft. Beta-score is a composite score that reflects pancreatic islet graft function after transplantation and measured from the following criteria: severe hypoglycemia, HbA1c, stimulated C-peptide, fasting glucose, insulin dose or oral diabetes, glycemic variability. 6 months in average before second islet graft